Eli Lilly has committed an additional $4.5 billion across two manufacturing sites in Lebanon, Indiana, taking its total Indiana capital expansion commitments since 2020 to more than $21 billion. The investment also marks the opening of Lilly Lebanon Advanced Therapies, the company’s first dedicated genetic medicine manufacturing facility.
The Foundayo launch impact on Eli Lilly has been swift and sharp — while FDA approval of orforglipron marked a historic first for oral GLP-1 obesity treatment, early prescription data trailing Novo Nordisk’s Wegovy sent LLY stock down as much as 4.3%, forcing analysts to slash 2026 revenue forecasts from $5 billion to just $1.3–1.6 billion.
Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.
New clinical data reveals that oral semaglutide (Wegovy pill) offers greater weight loss efficacy and significantly better GI tolerability than orforglipron.
Eli Lilly has officially received Foundayo FDA approval for orforglipron, the first daily non-peptide oral GLP-1 receptor agonist that offers significant weight loss results without the dietary restrictions of previous oral treatments.
